使用Mavacamten在患有阻塞性多变性心肌病的患者中的临床结果,使用真实世界的数据
Nirav Patel1, Mokshad Gaonkar1, Akhil Pampana1
1Division of Cardiovascular Disease, University of Alabama at Birmingham.
Mayo Clinic proceedings
|October 16, 2025
概括
与标准护理相比,Mavacamten治疗显著降低了阻塞性增高性心肌病 (oHCM) 患者的心血管风险. 这些现实数据表明,mavacamten是有效和安全的,心力衰竭风险低,射出率降低 (HFrEF).
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据研究研究.
背景情况:
- 阻塞性增高性心肌病变 (oHCM) 是一种重要的心血管疾病.
- 目前对oHCM的管理策略旨在改善患者的治疗结果并减少不良事件.
- 马瓦卡门代表了对oHCM的新治疗方法.
研究的目的:
- 评估Mavacamten治疗与心血管结果之间的关联.
- 为了比较vavacamten的疗效和安全性与oHCM患者的标准医疗管理.
- 为了评估vavacamten在大量患者队列中的实际有效性.
主要方法:
- 来自TriNetX网络的电子健康记录的回顾性分析 (2022年4月 - 2024年8月).
- 使用ICD-10代码和药物记录识别接受vavacamten或标准医疗管理的oHCM患者.
- 主要综合结局:心室高心率,心室动,心脏骤停或因任何原因死亡率. 考克斯的比例危险模型与反向概率权重被用于风险估计.
主要成果:
- 这项研究包括12,784名oHCM患者 (550名mavacamten,12,234名标准护理).
- 马瓦卡门治疗与复合心血管结局的风险明显降低相关 (HR,0.51;P=.026).
- 在这两组中,心力衰竭与减少射出分数 (HFrEF) 的发生率很低 (<1%),这表明安全性.
结论:
- 马瓦卡门治疗与基于真实数据的oHCM患者心血管不良结果的减少有关.
- 风险评估和缓解策略 (REMS) 计划在确保患者安全和缓解HFrEF风险方面显得有效.
- 进一步的研究是有必要的,以证实这些发现,由于观测性质和低事件率.
更多相关视频
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.6K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.9K
相关概念视频
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
399
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
399
01:29Cardiomyopathy V: Interprofessional Care
335
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
335
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
449
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
449
01:26Mitral Stenosis III: Medical Management
245
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
245
01:30Cardiomyopathy II: Dilated Cardiomyopathy
464
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
464
01:25Mitral Regurgitation III: Medical Management
274
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
274